Obstructive sleep apnoe and cardiovascular, heart failure and mortality outcomes with empagliflozin versus placebo in the EMPA-REG OUTCOME trial

被引：0
|
作者：
Yaggi, H. K. [1 ]
Eliasson, B. [2 ]
Kasai, T. [3 ]
Marx, N. [4 ]
Zinman, B. [5 ]
Inzucchi, S. E. [1 ]
Wanner, C. [6 ]
Zwiener, I [7 ]
Wojeck, B. [1 ]
Neeland, I [8 ]
Johansen, O. [9 ]
机构：
[1] Yale Univ, Yale Sch Med, New Haven, CT USA
[2] Sahlgrens Acad, Gothenburg, Sweden
[3] Juntendo Univ, Dept Cardiovasc Med, Grad Sch Med, Tokyo, Japan
[4] RWTH Univ Hosp Aachen, Aachen, Germany
[5] Univ Hlth Network, Mt Sinai Hosp, Toronto, ON, Canada
[6] Univ Hosp Wurzburg, Wurzburg, Germany
[7] Boehringer Ingelheim GmbH & Co KG, Ingelheim, Germany
[8] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA
[9] Boehringer Ingelheim GmbH & Co KG, Hovik, Norway
来源：
EUROPEAN HEART JOURNAL | 2020年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2883 / 2883
页数：1
相关论文
共 50 条
  • [11] Empagliflozin and Obstructive Sleep Apnea (OSA): Exploratory Analysis from the EMPA-REG OUTCOME Trial
    Neeland, Ian J.
    Eliasson, Bjorn
    Kasai, Takatoshi
    Marx, Nikolaus
    Zinman, Bernard
    Inzucchi, Silvio E.
    Wanner, Christoph
    Zwiener, Isabella
    Wojeck, Brian S.
    Yaggi, Henry K.
    Johansen, Odd Erik
    DIABETES, 2020, 69
  • [12] Heart failure outcomes with empagliflozin in patients with type 2 diabetes at high cardiovascular risk: results of the EMPA-REG OUTCOME® trial
    Fitchett, David
    Zinman, Bernard
    Wanner, Christoph
    Lachin, John M.
    Hantel, Stefan
    Salsali, Afshin
    Johansen, Odd Erik
    Woerle, Hans J.
    Broedl, Uli C.
    Inzucchi, Silvio E.
    Aizenberg, D.
    Ulla, M.
    Waitman, J.
    De Loredo, L.
    Farias, J.
    Fideleff, H.
    Lagrutta, M.
    Maldonado, N.
    Colombo, H.
    Ferre Pacora, F.
    Wasserman, A.
    Maffei, L.
    Lehman, R.
    Selvanayagam, J.
    d'Emden, M.
    Fasching, P.
    Paulweber, B.
    Toplak, H.
    Luger, A.
    Drexel, H.
    Prager, R.
    Schnack, C.
    Schernthaner, G.
    Fliesser-Goerzer, E.
    Kaser, S.
    Scheen, A.
    Van Gaal, L.
    Hollanders, G.
    Kockaerts, Y.
    Capiau, L.
    Chachati, A.
    Persu, A.
    Hermans, M.
    Vantroyen, D.
    Vercammen, C.
    Van de Borne, P.
    Mathieu, C.
    Benhalima, K.
    Lienart, F.
    Mortelmans, J.
    EUROPEAN HEART JOURNAL, 2016, 37 (19) : 1526 - 1534
  • [13] Empagliflozin Improves Kidney Outcomes in Patients With or Without Heart Failure Insights From the EMPA-REG OUTCOME Trial
    Butler, Javed
    Zannad, Faiez
    Fitchett, David
    Zinman, Bernard
    Koitka-Weber, Audrey
    von Eynatten, Maximilian
    Zwiener, Isabella
    George, Jyothis
    Brueckmann, Martina
    Cheung, Alfred K.
    Wanner, Christoph
    CIRCULATION-HEART FAILURE, 2019, 12 (06)
  • [14] Empagliflozin and kidney outcomes in patients with or without heart failure at baseline: insights from the EMPA-REG OUTCOME trial
    Butler, J.
    Zannad, F.
    Fitchett, D.
    Zinman, B.
    Koitka-Weber, A.
    von Eynatten, M.
    Hehnke, U.
    George, J.
    Brueckmann, M.
    Cheung, A. K.
    Wanner, C.
    DIABETOLOGIA, 2018, 61 : S323 - S323
  • [15] Effect of empagliflozin on heart failure outcomes in subgroups by age: results from EMPA-REG OUTCOME
    Monteiro, P.
    Schaper, N.
    Clark, D.
    Hantel, S.
    Woerle, H. J.
    Inzucchi, S. E.
    Fitchett, D.
    EUROPEAN HEART JOURNAL, 2016, 37 : 1191 - 1192
  • [16] Effect of Empagliflozin on Heart Failure Outcomes in Subgroups by Age: Results from EMPA-REG Outcome
    Monteiro, Pedro
    Schaper, Nicolaas
    Clark, Douglas
    Hantel, Stefan
    Woerle, Hans J.
    Inzucchi, Silvio E.
    Fitchett, David
    DIABETES, 2016, 65 : A291 - A291
  • [17] EFFECT OF EMPAGLIFLOZIN ON HEART FAILURE OUTCOMES IN SUBGROUPS BY AGE: RESULTS FROM EMPA-REG OUTCOME
    Lee, Dae Wook
    Monteiro, Pedro
    Clark, Douglas
    Hantel, Stefan
    Woerle, Hans J.
    Inzucchi, Silvio E.
    Fitchett, David
    JOURNAL OF HYPERTENSION, 2016, 34 : E520 - E520
  • [18] Effect of empagliflozin on heart failure outcomes in subgroups by age: results from EMPA-REG OUTCOME
    Monteiro, P.
    Schaper, N.
    Clark, D.
    Hantel, S.
    Woerle, H. -J.
    Inzucchi, S. E.
    Fitchett, D.
    DIABETOLOGIA, 2016, 59 : S534 - S534
  • [19] Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrumof heart failure risk in the EMPA-REG OUTCOME® trial
    Fitchett, David
    Butler, Javed
    van de Borne, Philippe
    Zinman, Bernard
    Lachin, John M.
    Wanner, Christoph
    Woerle, Hans J.
    Hantel, Stefan
    George, Jyothis T.
    Johansen, Odd Erik
    Inzucchi, Silvio E.
    Aizenberg, D.
    Ulla, M.
    Waitman, J.
    De Loredo, L.
    Farias, J.
    Fideleff, H.
    Lagrutta, M.
    Maldonado, N.
    Colombo, H.
    Ferre Pacora, F.
    Wasserman, A.
    Maffei, L.
    Lehman, R.
    Selvanayagam, J.
    d'Emden, M.
    Fasching, P.
    Paulweber, B.
    Toplak, H.
    Luger, A.
    Drexel, H.
    Prager, R.
    Schnack, C.
    Schernthaner, G.
    Fliesser-Goerzer, E.
    Kaser, S.
    Scheen, A.
    Van Gaal, L.
    Hollanders, G.
    Kockaerts, Y.
    Capiau, L.
    Chachati, A.
    Persu, A.
    Hermans, M.
    Vantroyen, D.
    Vercammen, C.
    Van de Borne, P.
    Mathieu, C.
    Benhalima, K.
    Lienart, F.
    EUROPEAN HEART JOURNAL, 2018, 39 (05) : 363 - 370
  • [20] MEDIATORS OF THE EMPAGLIFLOZIN TREATMENT EFFECT ON KIDNEY OUTCOMES IN THE EMPA-REG OUTCOME TRIAL
    Jardine, M.
    Wanner, C.
    Nangaku, M.
    Kraus, B.
    Zinman, B.
    Mattheus, M.
    Hantel, S.
    Schumacher, M.
    Ohneberg, K.
    Schmoor, C.
    Inzucchi, S. E.
    NEPHROLOGY, 2021, 26 : 19 - 19
12345